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Abstract:	   	  	  In	  this	  issue,	  Thomas	  et	  al.	  (2017)	  define	  the	  nature	  of	  accumulated	  ssDNA	  present	  in	  the	  neuron	  and	  astrocyte	  cytoplasm	  of	  TREX1	  mutated	  stem	  cell-­‐derived	  organoids.	  Accumulated	  ssDNAs	  are	  derived	  from	   LINE-­‐1	   endogenous	   retroelements,	   providing	   new	   clues	   as	   to	   the	   development	   of	   Aicardi-­‐Goutières	  syndrome	  in	  the	  neural	  system.	  	  	   Aicardi-­‐Goutières	   syndrome	   (AGS)	   is	   a	   rare	   recessive	   neurological	   brain	   disease	   caused	   by	  mutations	   in	  one	  of	   several	  genes,	  among	  which	   three-­‐prime	  repair	  exonuclease	   I	   (TREX1)	  was	   first	  identified.	  This	  finding	  opened	  a	  new	  avenue	  of	  research,	  as	  TREX1’	  3´-­‐	  5´exonuclease	  activity	  proved	  important	  in	  limiting	  the	  cellular	  accumulation	  of	  nucleic	  acids,	  such	  as	  single	  stranded	  DNA	  (ssDNA),	  which	  activates	  innate	  immune	  responses	  to	  viruses	  and	  the	  production	  of	  type	  I	  interferon	  that	  may	  lead	  to	  the	  development	  of	  systemic	  lupus	  erythematosus	  (SLE)-­‐like	  symptomatology.	  	  	   Long	  INterspersed	  Element	  class	  1	  elements	  (LINE-­‐1	  or	  L1	  retroelements)	  are	  very	  abundant	  in	  most	  mammalian	  genomes	  and	  comprise	  more	   than	  20%	  of	  human	  and	  mouse	  genomes	   (Garcia-­‐Perez	   et	   al.,	   2016).	   However,	   and	   despite	   their	   abundance,	   only	   a	   small	   fraction	   of	   these	   LINE-­‐1	  sequences	  are	  currently	  active.	  LINE-­‐1s	  are	  highly	  active	  in	  the	  nervous	  system,	  and	  TREX1	  is	  one	  key	  regulatory	   protein	   known	   to	   inhibit	   the	   overactivity	   of	   LINE-­‐1,	   suggesting	   that	   endogenous	  retroelements	   could	   be	   linked	   to	   the	   development	   of	   AGS.	   It	   has	   been	   suggested	   that	   endogenous	  retroelements	  may	  play	  a	  role	  in	  the	  development	  of	  autoimmunity	  and	  particularly	  in	  SLE	  (Perl	  et	  al.,	  2010).	   Stetson	   and	   colleagues	   (Stetson	   et	   al.,	   2008)	   showed	   that	   TREX1	   could	   metabolize	   ssDNA	  derived	   from	   endogenous	   retroelements	   that	   accumulate	   in	   Trex1	   deficient	   mice.	   They	   also	  demonstrated	   how	   Trex1	   controls	   the	   retrotransposition	   rate	   of	   LINE-­‐1s.	   Similarly,	   a	   more	   recent	  study	  also	  demonstrated	  that	  SAMHD1,	  a	  gene	  also	  involved	  in	  AGS,	  controls	  the	  rate	  of	  human	  LINE-­‐1	  retrotransposition	   in	   cultured	   cells	   (Zhao	   et	   al.,	   2013),	   although	   the	   mechanism	   is	   not	   completely	  clear.	  	   In	  this	  issue,	  Thomas	  et	  al.	  (Thomas,	  2017)	  further	  clarify	  the	  connection	  between	  endogenous	  retroelements	   and	   AGS.	   They	   develop	   a	   human	   stem	   cell-­‐derived	   cortical	   organoid	   model	   using	  pluripotent	   stem	   cells	   derived	   from	   patients	   with	   AGS	   or	   produced	   using	   CRISPR/Cas9	   genomic	  editing	   to	   introduce	   damaging	   mutations	   in	   the	   TREX1	   gene.	   In	   addition,	   the	   organoids	   help	   the	  authors	  to	  closely	  analyse	  the	  mutations’	  effects	  in	  neural	  tissue,	  a	  target	  of	  the	  disease,	  allowing	  the	  dissection	   of	   the	   role	   of	   various	   cell	   types.	   Furthermore,	   a	   major	   finding	   of	   this	   study	   is	   the	  demonstration	  that	  ONLY	  active	  LINE-­‐1	  elements	  are	  indeed	  related	  to	  AGS	  pathology.	  Active	  LINE-­‐1s	  are	  non-­‐LTR	  retrotransposons	  that	  move	  by	  a	  copy	  and	  paste	  mechanism,	  using	  an	  intermediate	  RNA	  and	   Reverse	   Transcriptase	   Activity	   (Garcia-­‐Perez	   et	   al.,	   2016),	   in	   a	   process	   known	   as	  retrotransposition.	   To	   do	   that,	   mammalian	   LINE-­‐1s	   encode	   two	   key	   enzymatic	   activities:	  	  ENdonuclease	  (EN)	  and	  Reverse	  Transcriptase	  (RT)	  (Figure	  1A),	  and	  both	  activities	  are	  required	  for	  their	  mobility	  in	  generating	  new	  genomic	  insertions	  distributed	  randomly	  in	  genomes	  (Figure	  1B).	  	  	   	  	  	   Thomas	   and	   colleagues	   provide	   compelling	   evidence	   suggesting	   that	   active	   LINE-­‐1	   elements	  generate	   abundant	   cytoplasmic	   LINE-­‐1-­‐derived	   single	   stranded	   DNA	   (ssDNA)	   molecules	   in	   TREX1	  mutant	   cells.	   Although	   this	   finding	   is	   supported	   by	   the	   use	   of	   chemical	   inhibitors	   of	   the	   LINE-­‐1-­‐encoded	  RT	   and	   genetic	   approaches	   to	   reduce	   LINE-­‐1	   activity,	  major	  mechanistic	   questions	   remain	  
unexplored.	  It	  is	  not	  clear	  whether	  cytoplasmic	  ssDNAs	  are	  indeed	  generated	  in	  TREX1	  mutant	  cells.	  A	  likely	  scenario	  is	  that	  these	  ssDNAs	  are	  abortive	  LINE-­‐1	  retrotransposition	  intermediates	  (Figure	  1B)	  that	  might	  gain	  access	  to	  the	  cytoplasm;	  these	  abortive	  LINE-­‐1	  intermediates	  might	  be	  over-­‐produced	  in	   the	   absence	   of	   TREX1	   activity,	   which	   normally	   might	   act	   to	   titrate	   the	   number	   of	   new	   LINE-­‐1	  insertions	  that	  a	  cell	  would	  normally	  accommodate.	  However,	  it	  is	  also	  possible	  that	  these	  ssDNAs	  are	  generated	  directly	  in	  the	  cytoplasm	  of	  TREX1	  mutant	  cells,	  although	  it	  is	  not	  clear	  how	  these	  ssDNAs	  might	   be	   primed.	   Either	  way,	   it	   is	   clear	   that	   these	   ssDNAs	   generated	  by	   active	   LINE-­‐1s	   are	   directly	  implicated	  in	  the	  pathophysiology	  of	  TREX1	  mutant	  cells,	  and	  presumably	  of	  AGS	  patients.	  This	  data	  is	  remarkable,	  as	  it	  provides	  the	  first	  clear	  demonstration	  that	  active	  LINE-­‐1s,	  and	  only	  active	  LINE-­‐1s,	  might	   be	   directly	   related	   to	   human	   AGS	   pathology.	   In	   addition,	   these	   data	   might	   help	   clarify	   why	  mouse	  models	  of	  AGS	  do	  not	  recapitulate	  the	  major	  symptoms	  observed	  in	  human	  AGS	  patients;	  it	  is	  tempting	   to	   speculate	   that	   as	   mouse	   cells	   normally	   deal	   with	   an	   excess	   of	   active	   LINE-­‐1s	  (approximately	  3000	  active	  LINE-­‐1s/mouse	  cells),	  they	  have	  greater	  tolerance	  to	  cytoplasmic	  ssDNAs	  before	   eliciting	   an	   autoimmune	   reaction	   than	   human	   cells,	   which	   normally	   deal	   with	   just	   80-­‐100	  active	  LINE-­‐1s/human	  cell.	  	   These	  results	  have	  additional	  important	  implications.	  For	  the	  first	  time,	  a	  tissue	  specific	  effect	  of	   TREX1	   is	   observed	   where	   on	   the	   one	   hand,	   neurons	   become	   importantly	   affected	   and	   suffer	  apoptosis,	   something	   that	   does	   not	   occur	   in	   neural	   precursors	   or	   in	   astrocytes	   (Thomas,	   2017).	  However,	   and	   importantly,	   astrocytes	   produce	   type	   I	   IFN	   following	   the	   accumulation	   of	   LINE-­‐1-­‐derived	  ssDNA,	  which	  increased	  the	  toxic	  effects	  to	  which	  neurons	  were	  subjected.	  	  	   Clinically,	  this	  study	  not	  only	  provides	  a	  plausible	  explanation	  for	  the	  microcephaly	  observed	  in	  AGS,	   but	   also	   provides	   hints	   as	   to	   the	   development	   of	   neuropsychiatric	   lupus.	   Patients	  with	  AGS	  caused	  by	  any	  of	  the	  genes	  with	  damaging	  mutations	  have	  increased	  activity	  of	  type	  I	  interferon	  in	  the	  cerebrospinal	  fluid,	  and	  patients	  rapidly	  develop	  neurological	  disabilities	  (Crow	  et	  al.,	  2015).	  Although	  contrary	   to	   previous	   belief,	   it	   has	   now	  been	   accepted	   that	   a	   larger	   proportion	   of	   patients	  with	   SLE	  show	  neuropsychiatric	  manifestations.	  In	  fact,	  neuroimaging	  evidence	  suggests	  that	  early	  cases	  of	  SLE,	  without	   neurological	   symptomatology,	   suffer	   from	   glucose	   hypometabolism	   consistent	   with	   early	  apoptosis	  or	  atrophy	  in	  portions	  of	  the	  frontal	  and	  parietal	  cortex,	  as	  well	  as	  inflammation	  (Ramage	  et	  al.,	  2011).	  It	  would	  be	  of	  interest	  to	  investigate	  if	  there	  is	  a	  relationship	  between	  TREX1	  heterozygous	  mutations	  and	  the	  presence	  of	  apoptosis	  and	  atrophy	  changes	  early	  in	  these	  patients.	  Furthermore,	  in	  general,	   neuroimaging	  monitoring	  of	   SLE	  patients	  with	  TREX1	  mutations	  may	   suggest	   the	   excessive	  production	  of	  type	  I	  IFN	  activity	  in	  the	  brain,	  and	  analysis	  of	  cerebrospinal	  fluid	  to	  show	  this,	  might	  be	  recommended	  in	  the	  clinic.	  TREX1	  may	  lie	  behind	  a	  larger	  proportion	  of	  neuropsychiatric	  SLE	  (Fredi	  et	  al.,	  2015)	  patients,	  who	  in	  addition	  with	  AGS	  patients,	  would	  be	  good	  candidates	  for	  very	  early	  anti-­‐type	   I	   IFN	   receptor	   treatment	   currently	   in	   clinical	   trials	   that	   may	   help	   them	   avoid	   critical	   brain	  damage.	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Figure	   1.	   A.	   Structure	   of	   a	   human	   active	   LINE-­‐1	   element.	   The	   relative	   position	   of	   the	  5´UnTranslated	   Region	   (5´UTR,	   grey	   box),	   ORF1p	   (yellow	   box),	   ORF2p	   (blue	   box)	   and	   3´UTR	   is	  indicated.	  Within	  ORF2p,	   the	   relative	  position	  of	   the	  endonuclease	   (EN),	   reverse	   transcriptase	   (RT),	  and	   cysteine-­‐rich	   (C)	   domain	   are	   also	   indicated.	   B.	  One	   round	   of	   LINE-­‐1	   retrotransposition	   by	  
Target	   Primed	   Reverse	   Transcription	   (TPRT).	   The	   endonuclease	   (EN)	   and	   reverse	   transcriptase	  (RT)	  enzymatic	  activities	  of	  LINE-­‐1	  are	  encoded	  within	  Open	  Reading	  Frame	  2	  (ORF2)	  of	  active	  LINE-­‐1	  elements,	   and	   both	   activities	   are	   strictly	   required	   for	   successful	   LINE-­‐1	   retrotransposition.	   Upon	  transcription	  and	   translation,	  both	  LINE-­‐1-­‐encoded	  proteins	   (ORF1p	  and	  ORF2p)	  bind	  back	   to	   their	  encoding	  mRNA	   by	   a	   process	   termed	   cis-­‐preference,	   and	   this	   complex	   gains	   access	   to	   the	   nucleus.	  Once	   in	   the	  nucleus,	   the	  EN	  activity	  of	  LINE-­‐1	  processes	   the	  bottom	  strand,	   releasing	  a	  3´OH	   that	   is	  used	  by	   the	  RT	  activity	   to	  generate	   the	   first	  cDNA	  strand	  of	   the	  new	  insertion,	  already	   linked	  to	   the	  genome.	  	  	  
